Mutares Stock Sinks Below Key Technical Level as Insider Sale Compounds Unease Over Deal Pipeline

The past week delivered a double blow to Mutares’ share price. An insider sale and a breach of the 200-day moving average sent the stock sliding more than 5% in five sessions, even as the Munich-based holding company pressed ahead with a flurry of portfolio moves.

On 19 June 2026, supervisory board member Dr.-Ing. Kristian Schleede disposed of roughly 3,000 shares at prices ranging from €29.15 to €29.225. The trade was reported to BaFin on 24 June, by which point the stock was still trading near those levels. But selling pressure intensified after the shares slipped below the 200-day line at €28.95 on 26 June, closing the week at €27.95 — about €1.20 below the insider sale price. The stock now sits roughly 23% beneath its 52-week high of €36.40, with a year-to-date decline of nearly 6%.

The technical breakdown comes at a time when Mutares is reshaping its portfolio at breakneck speed. In June alone, management closed several transactions. The most significant is the planned exit of NEM Energy to Hyundai Heavy Industries. The price is undisclosed — both sides agreed to keep it confidential — and completion is targeted for the third quarter of 2026.

Alongside that, the group continues to explore options for fire-truck specialist Magirus. A sale or an initial public offering are both on the table, with the final decision hinging on market conditions. Magirus brings substantial heft: its order book has swelled to over €880 million, providing visibility well into 2027. In fiscal 2025 the unit generated around €336 million in revenue. Its defense arm, built partly through the acquisition of Achleitner Fahrzeugbau, is also expanding.

Should investors sell immediately? Or is it worth buying Mutares?

On the acquisition side, Mutares is buying Synthomer’s specialty chemicals business in the Czech Republic. The purchase price is zero upfront, but an earn-out of up to €12 million will be paid over three years. The deal strengthens the Chemicals & Materials segment, which the company is actively building as a second pillar alongside the planned takeover of SABIC’s plastics business.

Management is also addressing the balance sheet. The outstanding bond volume is being trimmed from €385 million down to €250 million by end of 2026. In the nearer term, the target is to cut it to no more than €300 million, with at least €25 million in quarterly buybacks. For the full year, Mutares expects revenue to exceed €8 billion (the formal guidance range is €7.9 billion to €9.1 billion) and a net profit of at least €165 million (with a holding profit target of €165 million to €200 million). For fiscal 2025, the board has proposed a dividend of €2.00 per share as a minimum, with an additional performance dividend tied to successful exits.

Despite this deal activity, the stock has yet to catch up. Warburg Research recently trimmed its price target to €41 but maintained a “Buy” rating. The analyst noted that the announced exits need to translate quickly into the profit-and-loss statement for the valuation gap to close. Whether the second half delivers those results — starting with the NEM Energy closing in Q3 and the next step for Magirus — will determine if Mutares can reverse the recent slide.